Highlights from Chiesi Group's 2023 financial report: Sales increased to over €3 billion, up 10% compared to 2022 (+12% @CER), driven by the Rare business unit growth (65% @CER), and steady growth of all products in all its Regions 24% of 2023 sales were devoted to R&D to create innovative therapeutic solutions, focused on the needs of patients, caregivers and the entire healthcare community Profitability remained around 30% for the fourth consecutive year enabling the Company to pursue its expansion strategy. PARMA, Italy, April 22, 2024 /PRNewswire/ -- In 2023, Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma (Italy), with 31 affiliates worldwide, showcased the efficacy of its operating model centred around shared value, sustainability, and high ethical standards. Through this approach, Chiesi continues to deliver tangible benefits for patients, people, and the planet. 2023 business growth serving patient needs Chiesi reached over €3 billion in sales – a 10% growth (+12% @CER) on the previous year – maintaining an EBIDTA of approximately 30% for the fourth consecutive year. Group Revenues 2022 2023 Growth @CER Total €2,749M €3,026M 12 % Air €1,634M €1,708M 6 % Rare €332M €540M 65 % Care €783M €778M 2 % Financials 2022 2023 Growth EBITDA €827M €893M 8 % EBITDA % 30.1 % 29.5 % In 2023, the Company reinforced its strong momentum across geographies and business areas. At constant exchange rates (@CER), growth was observed in all three of the Group's business areas (AIR - respiratory diseases, RARE - rare and ultra-rare diseases, and CARE - specialty care, neonatology and consumer healthcare) and across all its Regions (US grew at 25%, Europe at 7% and China ...